Immunogenicity, Reactogenicity of Shingrix in SLE

NCT06001606 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Zoster
Systemic Lupus Erythematosus
Vaccine Reaction

Interventions

DRUG: Shingrix
DRUG: Placebo

Sponsor

Seoul National University Hospital